ACTG Presents SLIM LIVER Findings at AASLD Liver Meeting Demonstrating Improvements in Biomarkers of Cardiovascular Risk among People Living with HIV and MASLD Who Receive Semaglutide

Article content

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced data finding that treating people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD) with semaglutide significantly improved a variety of biomarkers of cardiovascular risk. These results from the SLIM LIVER study (also known as A5371) will be shared as a poster presentation, “Semaglutide Improves Markers of Cardiovascular Risk in People with HIV: The SLIM LIVER Study” today, Monday, November 10, at 1:00 pm ET at the 2025 AASLD Liver Meeting, taking place in Washington D.C.

Article content

Article content

SLIM LIVER was the first clinical trial to test semaglutide as a treatment for MASLD in people living with HIV. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a common and serious condition in which fat builds up in the liver. In people living with HIV, MASLD may cause faster liver damage and increase the risk of organ dysfunction compared to people who have MASLD but not HIV. While semaglutide (a commonly used treatment for weight loss and diabetes) has been associated with cardiometabolic improvements in the general population, the previously presented primary analysis of SLIM LIVER showed for the first time that semaglutide improved, and in some cases resolved completely, MASLD among people living with HIV. At the Liver Meeting, SLIM LIVER will also show improvements in novel biomarkers of cardiovascular risk.

Article content

Article content

Article content

“This SLIM LIVER analysis provides important insights into the impact of semaglutide on a whole host of cardiovascular biomarkers for people living with HIV and MASLD,” said ACTG Chair Joseph J. Eron, M.D., University of North Carolina. “People living with HIV are at increased risk for cardiovascular disease and they experience MASLD in greater numbers than the general population. ACTG is committed to conducting research that identifies solutions to the comorbidities that most impact people living with HIV and we are encouraged by these results.”

Article content

Article content

Today’s Liver Meeting presentation expands upon previous data among people living with HIV and MASLD finding that semaglutide improved weight, intra-hepatic triglyceride content, insulin resistance, glucose, and triglycerides. The current analysis included 36 people living with HIV taking antiretroviral therapy (ART) with MRI-defined MASLD.

Article content

Participants had a median age of 52 years and median BMI of 34 kg/m²; 39 percent were Hispanic, 28 percent were Black, 45 percent were female; and 77 percent were taking an ART regimen that contained an integrase inhibitor. In this analysis, researchers identified significant reductions in cardiovascular risk-associated lipoproteins and glycoproteins that were not related to the changes in weight, liver fat, or insulin resistance reported in the primary analysis, which suggests that semaglutide has an independent mechanism contributing to those changes.

Article content

“MASLD is increasingly recognized as a major contributor to illness and death among people living with HIV, so identifying treatments that can attenuate its impact is an important priority in HIV research,” said lead author Jordan E. Lake, M.D., M.Sc., UTHealth Houston. “While larger studies with clinical endpoints are still needed to optimize cardiovascular risk among people living with HIV and MASLD, these findings are an important first step in understanding the impact of semaglutide among these individuals and have the potential to meaningfully impact their health.”